Similar to the effects of CDKIs, antagonism of protein kinase B (AKT) and 3-phosphoinositide-dependent protein kinase 1 (PDK1) produce a similar reduction in tumor growth and progression via cancer cell senescence. Here, AKT1 is linked to cancer.